Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
Revolution Medicines, Inc.
Verastem, Inc.
AstraZeneca
Hoffmann-La Roche
University of Chicago
Alliance for Clinical Trials in Oncology
Amgen
Bristol-Myers Squibb
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Merck Sharp & Dohme LLC
BioNTech SE
Massachusetts General Hospital
Taiho Oncology, Inc.
Regeneron Pharmaceuticals
NRG Oncology
Eli Lilly and Company
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
National Cancer Institute (NCI)
Jiangsu HengRui Medicine Co., Ltd.
Lantern Pharma Inc.
University of Kentucky
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Swiss Cancer Institute
Latin American Cooperative Oncology Group